Pulse Medical Snags $100 Million in a Series C Financing

(VCBeat) Aug. 2, 2021 -- Pulse Medical Imaging Technology (Shanghai) Co., Ltd. ("Pulse Medical"), an industry leader in the accurate diagnosis and treatment with vascular and interventional radiology, announced the completion of a Series C financing of over $100 million, co-led by the existing investor GL Ventures and the strategic investor Philips, Goldman Sachs, and Boyu Capital, with participation from Linden Asset Group, Insight Capital, etc. Haoyu Capital acted as the exclusive financial advisor for this round of financing.

The funds are earmarked for the commercialization of Pulse Medical's products, the research and development of new products, clinical registration, and further layout of interventional diagnosis and treatment.

Pulse Medical is dedicated to developing innovative technology for precise diagnosis and optimal treatment of patients with coronary artery disease. Together with its research partner Shanghai Jiao Tong University, Pulse Medical has been pioneering in the fast computation of fractional flow reserve (FFR) from multiple imaging data. The angiography-based approach (QFR) and intracoronary OCT-based approach (OFR) have been well received in the field of interventional cardiology as precise and affordable intra-procedural solutions for the evaluation of FFR in patients during diagnostic coronary angiography. 

Pulse Medical's products cover the precision screening of vascular diseases, intraoperative diagnosis and surgical planning, postoperative efficacy evaluation, and patient risk prediction. Up to now, the company has more than 70 patents from China, Germany, Japan, and other countries, and many of the world's first top technologies.

GL Ventures was set up by private equity heavyweight Hillhouse Capital to invest in emerging startups in February 2020. GL Ventures focuses on four areas: biomedicine and medical devices, software services and initiatives in tech innovations, consumer internet and technology, and emerging consumer brands and services.

Boyu Capital is a China-focused investment firm. Its mission is to deliver long-term risk-adjusted returns for the Fund's investors through a systematic and tailor-made investment approach. The company provides growth and transformational capital for fast-growing businesses in Greater China, as well as participating in the restructuring of state-owned enterprises.